Welcome to our dedicated page for Rhythm Pharmaceu SEC filings (Ticker: RYTM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Rhythm Pharmaceuticals, Inc. (RYTM) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, providing structured access to its public reporting. Rhythm is a commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases, and its filings offer insight into the development and commercialization of IMCIVREE (setmelanotide) and related MC4R agonist programs.
Investors can review current reports on Form 8‑K in which Rhythm discusses material events such as quarterly and annual financial results, FDA and EMA regulatory milestones, equity offerings, and amendments to its certificate of incorporation. For example, the company has filed 8‑Ks describing FDA Priority Review and PDUFA goal dates for a supplemental New Drug Application for IMCIVREE in acquired hypothalamic obesity, as well as an 8‑K detailing an underwritten public offering of common stock and intended use of proceeds.
While this page focuses on current reports and other SEC documents, it also serves as a gateway to Rhythm’s periodic reports, where investors typically find detailed information on revenue from global sales of IMCIVREE, research and development expenses, selling, general and administrative expenses, cash position and funding runway. These filings also describe clinical programs in acquired and congenital hypothalamic obesity, genetically caused MC4R pathway diseases and Prader-Willi syndrome, along with investigational agents bivamelagon and RM-718.
Stock Titan enhances these filings with AI-powered summaries that highlight key points, such as changes in operating expenses, financing transactions, or significant regulatory updates. Real-time ingestion from EDGAR helps surface new Rhythm filings quickly, and users can also monitor items that may relate to executive or director activity when Forms 3, 4 or 5 are filed. This combination of original documents and AI explanations is designed to make RYTM’s complex biopharmaceutical disclosures more accessible to a broad range of investors.
RYTM proposed sale of 35,460 common shares on 03/03/2026. The filing lists 35,460 shares tied to an exercise of options under a registered plan and an aggregate value of $3,209,778.92 on 03/03/2026. The transaction is reported through Morgan Stanley Smith Barney LLC on NASDAQ.
Rhythm Pharmaceuticals' Chief Financial Officer Hunter C. Smith acquired shares through an option exercise. On March 2, 2026, Smith exercised stock options for 6,099 options, which converted into 6,099 shares of common stock at an exercise price of $6.80 per share.
After these transactions, Smith directly held 91,401 stock options and 116,611 shares of common stock. The filing notes that the options involved in this exercise were fully vested.
Rhythm Pharmaceuticals, Inc. reported additional positive 52-week data from its global Phase 3 TRANSCEND trial of setmelanotide in acquired hypothalamic obesity. Across all 142 patients, including 12 from a Japanese cohort and 10 supplemental patients, treatment achieved a -18.8% placebo-adjusted difference in BMI reduction.
The company’s supplemental New Drug Application for setmelanotide in acquired hypothalamic obesity is under U.S. FDA review with a March 20, 2026 PDUFA goal date, and Rhythm will submit the final data package on March 2, 2026. In Europe, a Type II variation to the Marketing Authorization Application is under EMA review, with an expected CHMP opinion in the second quarter of 2026 and potential marketing authorization in the second half of 2026.
Rhythm also plans to submit the full data package to Japan’s PMDA to seek marketing authorization. The company estimates about 10,000 patients with acquired hypothalamic obesity in the United States, approximately 10,000 in Europe and 5,000 to 8,000 in Japan, highlighting a meaningful rare-disease population for this potential new indication.
Rhythm Pharmaceuticals, Inc. filed a shelf registration that registers resale of 2,395,831 shares of common stock issuable upon conversion of Series A Convertible Preferred Stock and a sales agreement to offer up to $200,000,000 of common stock under an at‑the‑market style arrangement with TD Securities (USA) LLC.
The selling stockholders’ resale will not provide proceeds to the company; the sales agreement permits the company to issue and sell shares from time to time after the effective date, with specific terms to be provided in prospectus supplements.
Rhythm Pharmaceuticals files its Annual Report outlining progress in rare obesity therapies. The company is a commercial-stage biopharma focused on melanocortin-4 receptor (MC4R) agonists, led by IMCIVREE (setmelanotide), and has generated approximately $422.5 million from product sales to date while remaining unprofitable.
IMCIVREE is already approved in the United States, European Union, United Kingdom and other regions for several rare MC4R pathway obesities, including Bardet-Biedl syndrome and biallelic POMC, PCSK1 and LEPR deficiencies, with use now extending to children as young as 2 years in key markets. A Phase 3 trial in acquired hypothalamic obesity showed a placebo‑adjusted body mass index reduction of 19.8%, supporting regulatory reviews in the United States and Europe, including an FDA PDUFA goal date of March 20, 2026.
Rhythm also highlights a broad pipeline: the Phase 3 EMANATE trial in multiple genetically defined MC4R pathway diseases with topline data expected in March 2026, positive exploratory data in Prader‑Willi syndrome, and two next‑generation MC4R agonists—oral bivamelagon, which produced up to a 9.3% BMI reduction in a Phase 2 hypothalamic obesity trial, and weekly injectable RM‑718. The company is investing in large-scale genetic testing and early research in congenital hyperinsulinism while warning that it will need additional funding and continues to face significant clinical, regulatory and commercial risks.
Rhythm Pharmaceuticals reported strong growth for the fourth quarter and full year 2025 while remaining loss-making. Net product revenue from global sales of IMCIVREE® was $57.3 million in the fourth quarter and $194.8 million for 2025, up from $41.8 million and $130.1 million in 2024. Cash, cash equivalents and short-term investments were $388.9 million as of December 31, 2025, compared with $320.6 million a year earlier, giving the company at least 24 months of operating runway based on current plans.
R&D expenses were $167.3 million in 2025, down from $238.0 million mainly due to non-recurring in-process R&D costs in 2024, while SG&A expenses rose to $194.9 million from $144.3 million as the company expanded headcount and commercial operations. Net loss attributable to common stockholders narrowed to $201.9 million in 2025 from $264.6 million in 2024, with loss per share improving to $3.11 from $4.34.
The company highlighted a March 20, 2026 PDUFA goal date for its supplemental application seeking approval of setmelanotide for acquired hypothalamic obesity, positive Phase 2 data for oral MC4R agonist bivamelagon, and multiple upcoming Phase 3 and Phase 2 data readouts in 2026. Rhythm guided to 2026 non-GAAP operating expenses of $385 million to $415 million, excluding stock-based compensation and certain in-licensing costs, reflecting continued investment in commercial expansion and its MC4R pathway pipeline.
Rhythm Pharmaceuticals Chief Financial Officer Hunter C. Smith reported open-market sales of a total of 7,954 shares of common stock on February 17 and 19, 2026, at prices generally around $100 per share.
The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 28, 2025. After these sales, Smith directly holds 110,512 shares of Rhythm Pharmaceuticals common stock.
Rhythm Pharmaceuticals EVP Yann Mazabraud reported equity award activity involving restricted stock units and common stock. On February 14, 2026, he exercised or converted 10,000 restricted stock units into 10,000 shares of common stock at a price of $0.00 per share, reflecting the non-cash nature of the award.
After these transactions, he directly held 30,000 restricted stock units and 53,155 shares of common stock. Each restricted stock unit represents a right to receive one share of common stock and vests in four 25% installments on February 14, 2026, February 1, 2027, February 1, 2028, and February 1, 2029.
RA Capital Management and affiliates reported a sizable passive stake in Pharmaceuticals, Inc. They beneficially owned 6,666,837 shares of common stock, representing 9.99% of the company’s outstanding shares as of December 31, 2025, based on 66,736,056 shares outstanding on October 31, 2025.
The shares are directly held by RA Capital Healthcare Fund, L.P., which has delegated sole voting and investment power to RA Capital Management, L.P. Individuals Peter Kolchinsky and Rajeev Shah may be deemed beneficial owners through their control of RA Capital, but all reporting persons disclaim beneficial ownership beyond Section 13(d) requirements.
The filers certify that the securities were not acquired and are not held for the purpose of changing or influencing control of the issuer, indicating a passive investment intent rather than an activist position.
Shulman Joseph, Chief Technical Officer of Pharmaceuticals, Inc., reported new equity awards. On February 11, 2026, he received 15,000 restricted stock units and stock options for 22,500 shares with a $98.47 exercise price, all held directly.
The restricted stock units vest in four equal 25% installments on February 1 of 2027, 2028, 2029 and 2030 and have no expiration date. The options were granted on February 11, 2026 and vest in 16 substantially equal installments, each after three full months of continued service, until fully exercisable by February 10, 2036.